Short answer
Medical device commercialization is everything that turns a cleared product into paid, repeat hospital use: reimbursement pathway, clinical and economic evidence, target account selection, pilot sites, and a repeatable sales motion. FDA clearance permits you to sell; commercialization is the work of getting a hospital to actually buy.
Commercialization is the work of getting a cleared device into hospitals, into procedures, and onto contracts on purpose rather than by accident. It's not the same job as sales, and treating it that way is the first mistake most teams make.
Commercialization is not just "sales"
Sales is one activity inside commercialization, not the whole job. A device can have a rep in the field and still have no commercial infrastructure behind them: no ranked list of which accounts matter, no evidence package a value analysis committee will accept, no read on which hospitals already have a competing device installed.
Commercialization is the full system that makes a sales conversation possible in the first place — who to target, what to bring to the meeting, and what has to be true (clinically, financially, operationally) before a hospital will say yes. Skip that system and even a talented sales hire is just guessing.
The four phases of commercialization
If you are working out how to commercialize a medical device for the first time, it helps to name the phases. Every device moves through the same four after clearance, whether or not a team makes them explicit.
Regulatory handoff
The regulatory and clinical teams who got the device cleared hand off to whoever owns commercial. This is where institutional knowledge quietly gets lost: the clinical evidence that mattered for FDA is not automatically packaged in a way that matters to a hospital's value analysis committee.
Market access
Before a single sales call, the team needs a real answer to "will this get paid for, here, for this patient population." Coding, coverage, and payer policy vary by region and by account. Get this wrong and every downstream conversation stalls at the same objection.
Pilot accounts
The first handful of hospitals are not really customers yet — they're proof. The goal isn't revenue, it's a working reference: a clinical champion, a completed case, and evidence that the device performs the way the label says it does.
Scale
Once pilots prove the model, the same playbook has to repeat across many more accounts without reinventing the targeting and evidence work from scratch every time. This is where teams either build real commercial infrastructure or stay stuck rebuilding the same manual work per account.
Where teams get stuck
Almost every delay traces back to one of three gaps.
No ranked target list
Without a defensible way to say which hospitals matter most, teams default to whichever accounts a rep already knows — not the same as whichever accounts are the best fit.
Evidence rebuilt every time
If the clinical and economic case is reassembled by hand for every account, the team is capped at however fast one person can write briefs — and that case has to answer who pays and who saves, not just whether the device works.
No visibility into execution
Leadership finds out an account has gone quiet, or a claim has drifted past what's cleared, weeks after it happened, because nothing tracked it in between.
None of these are hiring problems. They're infrastructure problems, and they're the reason teams that raise a Series B for a great device still take 12 to 18 months to get meaningful commercial traction.
How to prioritize your first 20 hospital targets
A short, practical way to build the first list without waiting for a perfect data system:
- 1
Start with procedure volume, not size
A large hospital with low volume in your specific procedure is a worse first target than a mid-size hospital doing the procedure every week.
- 2
Weight for an existing champion
A physician who already understands the clinical problem you solve shortens the sales cycle more than any other single factor.
- 3
Check the competitive install base
An account that just signed a multi-year deal with an incumbent is a poor first target, regardless of how good the fit looks otherwise.
- 4
Confirm who actually captures the value
As the Sim&Size example shows, a strong clinical and economic case still stalls if the account you're pitching isn't the one that benefits financially.
- 5
Keep the list to 20, not 200
A shorter list you can actually work with evidence and follow-up beats a long list that gets a form email and nothing else.
The infrastructure question
None of the four phases above requires more headcount to do well. They require a system that ranks accounts with real evidence, builds the case for each one without starting from a blank page, and shows leadership where execution — or a claim — is drifting before it becomes a Tablo-style reset.
That's the gap RevWorx is built to close. Teams that would otherwise spend 12 to 18 months assembling this manually can have a ranked target list, evidence-backed account plans, and a tracked execution path running in weeks instead. See how that works on our medical device commercialization strategy page.
Sources and notes
- Outset Medical / Tablo: clearance date, revenue figures, installed-base numbers, and the 2023 FDA findings are drawn from Outset Medical's public financial disclosures and FDA's published warning letter (July 5, 2023), with contemporaneous coverage in MedTech Dive and MassDevice. FDA warning letters are published in the FDA warning letter database.
- Sim&Cure / Sim&Size: the product description is public. The "who captures the savings" dynamic described here is presented as a pattern common in neurovascular device adoption, illustrated by Sim&Size, rather than a documented account of one company's procurement experience.
Frequently asked questions
- What are the phases of medical device commercialization?
- Four: regulatory handoff (translating your clearance into claims you can make), market access (coding, coverage, and payment), pilot accounts (a small set of reference sites that generate real-world evidence), and scale (repeating the motion across similar accounts). Skipping market access is the most common and most expensive mistake.
- How long does medical device commercialization take?
- A traditional commercial buildout runs 12 to 18 months from clearance to first meaningful contracts, mostly consumed by evidence, reimbursement work, and account discovery. Teams that prioritize a narrow beachhead and prepare payer and value-analysis materials in parallel compress that substantially.
- How do you prioritize your first hospital targets?
- Score accounts on procedure or patient volume in your indication, payer mix and whether local coverage exists, presence of a clinical champion, and how the account's buying committee works. Twenty well-scored targets beat a list of hundreds.
- Is FDA clearance enough to start selling?
- No. Clearance means you may market the device. Hospitals still require coding and payment clarity, evidence a value analysis committee will accept, and a budget owner. Products with clearance and no reimbursement path routinely stall for a year or more.